BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 16932606)

  • 1. Amyotrophic lateral sclerosis and gene therapy.
    Miller TM; Smith RA; Cleveland DW
    Nat Clin Pract Neurol; 2006 Sep; 2(9):462-3. PubMed ID: 16932606
    [No Abstract]   [Full Text] [Related]  

  • 2. RNAi therapy: dominant disease gene gets silenced.
    Xu Z; Xia XG
    Gene Ther; 2005 Aug; 12(15):1159-60. PubMed ID: 15858609
    [No Abstract]   [Full Text] [Related]  

  • 3. Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis.
    Miller TM; Kaspar BK; Kops GJ; Yamanaka K; Christian LJ; Gage FH; Cleveland DW
    Ann Neurol; 2005 May; 57(5):773-6. PubMed ID: 15852369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Gene therapy of ALS with RNA interference].
    Yokota T
    Rinsho Shinkeigaku; 2009 Nov; 49(11):821-3. PubMed ID: 20030220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lentiviral and adeno-associated vector-based therapy for motor neuron disease through RNAi.
    Towne C; Aebischer P
    Methods Mol Biol; 2009; 555():87-108. PubMed ID: 19495690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Has gene therapy for ALS arrived?
    Miller TM; Cleveland DW
    Nat Med; 2003 Oct; 9(10):1256-7. PubMed ID: 14520369
    [No Abstract]   [Full Text] [Related]  

  • 7. AAV6-mediated gene silencing fALS short.
    Mandel RJ; Lowenstein PR; Byrne BJ
    Mol Ther; 2011 Feb; 19(2):231-3. PubMed ID: 21289637
    [No Abstract]   [Full Text] [Related]  

  • 8. [Gene therapy of ALS with short interfering RNA].
    Yokota T
    Brain Nerve; 2007 Oct; 59(10):1187-94. PubMed ID: 17969360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental therapies hold promise for treating amyotrophic lateral sclerosis.
    Friedrich MJ
    JAMA; 2005 Mar; 293(9):1048-9. PubMed ID: 15741517
    [No Abstract]   [Full Text] [Related]  

  • 10. RNA interference protects against ALS in mouse model.
    Burton A
    Lancet Neurol; 2005 May; 4(5):274-5. PubMed ID: 15861555
    [No Abstract]   [Full Text] [Related]  

  • 11. Gene Therapy for ALS: progress and prospects.
    Azzouz M
    Biochim Biophys Acta; 2006; 1762(11-12):1122-7. PubMed ID: 16806843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis.
    Ding H; Schwarz DS; Keene A; Affar el B; Fenton L; Xia X; Shi Y; Zamore PD; Xu Z
    Aging Cell; 2003 Aug; 2(4):209-17. PubMed ID: 12934714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increase of disease duration of amyotrophic lateral sclerosis in a mouse model by transgenic small interfering RNA.
    Yokota T; Sasaguri H; Saito Y; Yamada H; Unno T; Yamamoto Y; Kubodera T; Anzai M; Mitani T; Mizusawa H
    Arch Neurol; 2007 Jan; 64(1):145-6. PubMed ID: 17210827
    [No Abstract]   [Full Text] [Related]  

  • 14. Research advances in gene therapy approaches for the treatment of amyotrophic lateral sclerosis.
    Nizzardo M; Simone C; Falcone M; Riboldi G; Rizzo F; Magri F; Bresolin N; Comi GP; Corti S
    Cell Mol Life Sci; 2012 May; 69(10):1641-50. PubMed ID: 22094924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An RNAi strategy for treatment of amyotrophic lateral sclerosis caused by mutant Cu,Zn superoxide dismutase.
    Xia XG; Zhou H; Zhou S; Yu Y; Wu R; Xu Z
    J Neurochem; 2005 Jan; 92(2):362-7. PubMed ID: 15663483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Finding a Treatment for ALS - Will Gene Editing Cut It?
    Al-Chalabi A; Brown RH
    N Engl J Med; 2018 Apr; 378(15):1454-1456. PubMed ID: 29641956
    [No Abstract]   [Full Text] [Related]  

  • 17. Oligonucleotide therapies: the future of amyotrophic lateral sclerosis treatment?
    Aoki Y; Douglas AG; Wood MJ
    Neurodegener Dis Manag; 2015; 5(2):93-5. PubMed ID: 25894871
    [No Abstract]   [Full Text] [Related]  

  • 18. siRNAs meet their match.
    Potash J
    Nat Methods; 2006 Nov; 3(11):876. PubMed ID: 17124734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS.
    Raoul C; Abbas-Terki T; Bensadoun JC; Guillot S; Haase G; Szulc J; Henderson CE; Aebischer P
    Nat Med; 2005 Apr; 11(4):423-8. PubMed ID: 15768028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model.
    Ralph GS; Radcliffe PA; Day DM; Carthy JM; Leroux MA; Lee DC; Wong LF; Bilsland LG; Greensmith L; Kingsman SM; Mitrophanous KA; Mazarakis ND; Azzouz M
    Nat Med; 2005 Apr; 11(4):429-33. PubMed ID: 15768029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.